Table 1.
Patient and treatment characteristics
| N (%) | |
|---|---|
| (n = 23 patients) | |
| Median age, years (IQR) | 71 (61–73) |
| Sex | |
| Male | 19 (82.6%) |
| Female | 4 (17.4%) |
| Race/Ethnicity | |
| White, Non-Hispanic | 21 (91.3%) |
| White, Hispanic | 2 (8.7%) |
| IMDC group | |
| Favorable | 17 (73.9%) |
| Intermediate | 6 (26.1%) |
| Histology | |
| Clear cell RCC | 19 (82.6%) |
| Chromophobe RCC | 2 (8.7%) |
| Papillary RCC | 2 (8.7%) |
| Tumor Grade | |
| 1 | 1 (4.3%) |
| 2 | 6 (26.1%) |
| 3 | 13 (56.5%) |
| 4 | 1 (4.3%) |
| NA (Chromophobe RCC) | 2 (8.7%) |
| Primary tumor control | |
| Nephrectomy | 22 (95.7%) |
| SAbR | 1 (4.3%) |
| AJCC T stage at initial diagnosis | |
| 1 | 4 (17.4%) |
| 2 | 3 (13.0%) |
| 3 | 16 (69.6%) |
| AJCC N stage at initial diagnosis | |
| 0/X | 22 (95.7%) |
| 1 | 1 (4.3%) |
| AJCC M stage at initial diagnosis | |
| 0 | 20 (87.0%) |
| 1 | 3 (13.0%) |
| STARS Stage | |
| A | 7 (30.4%) |
| B | 13 (56.5%) |
| C | 0 (0.0%) |
| D | 3 (13.0%) |
| E | 0 (0.0%) |
| Pattern of metastatic disease | |
| Metachronous | 16 (69.6%) |
| Synchronous | 7 (30.4%) |
| Prior therapy of metastases | |
| Prior SAbR | 4 (17.4%) |
| Prior resection | 3 (13.0%) |
| Prior resection & SAbR | 2 (8.7%) |
| Median baseline SLD, cm (IQR) | 2.4 (1.3–3.3) |
| Number of SAbR sites, initial | |
| 1 | 15 (65.2%) |
| 2 | 6 (26.1%) |
| 3 | 2 (8.7%) |
| Number of SAbR sites, total | |
| 1 | 8 (34.8%) |
| 2 | 7 (30.4%) |
| 3 | 3 (13.0%) |
| 4–7 | 5 (21.7%) |
| All sites treated with SAbR | (n = 57 lesions) |
| Lung | 27 (47.4%) |
| Abdominal LN | 6 (10.5%) |
| Bone, non-spine | 4 (7.0%) |
| Spine | 4 (7.0%) |
| Kidney | 3 (5.3%) |
| Adrenal | 3 (5.3%) |
| Liver | 3 (5.3%) |
| Thoracic LN | 3 (5.3%) |
| Pancreas | 1 (1.8%) |
| Renal bed | 1 (1.8%) |
| Chest wall | 1 (1.8%) |
| Psoas | 1 (1.8%) |
| SAbR fractionation | |
| 1 fraction | 3 (5.3%) |
| 3 fractions | 39 (68.4%) |
| 5 fractions | 15 (26.3%) |
| Median/mode dose, Gy (range) | |
| 1 fraction | 25/25 (20–25) |
| 3 fractions | 36/36 (36–39) |
| 5 fractions | 40/40 (35–40) |
Abbreviations: AJCC, American Joint Committee on Cancer staging 8th edition; IMDC, International Metastatic RCC Database Consortium; IQR, interquartile range; LN, lymph node; RCC, renal cell carcinoma; SAbR, stereotactic ablative radiotherapy; SLD, sum of the longest diameters.